FDA Expands Approval of Cardiac Ultrasound Imaging Agent for Pediatric Patients
The only ultrasound enhancing agent that does not contain polyethylene glycol, Optison may now be utilized to enhance echocardiogram assessment of ventricular function in pediatric patients.
The Food and Drug Administration (FDA) has approved an expanded indication that allows use of ultrasound enhancing agent Optison for pediatric patients with suboptimal echocardiograms.
Through the use of gas-filled microbubbles, Optison improves the visualization of heart chambers and endocardial borders, according to GE HealthCare, the manufacturer of Optison.
Recently approved for use in pediatric patients, the ultrasound enhancing agent Optison provided enhanced visualization of endocardial borders and ventricular wall segments for pediatric patients in a recent phase IV study. (Image courtesy of GE HealthCare.)
Originally approved by the FDA in 1997 for adult patients, Optison was the subject of a recent phase IV multicenter study. GE HealthCare said the study results revealed the effectiveness of the ultrasound enhancing agent in improving delineation of endocardial borders as well as imaging of ventricular wall segments in pediatric patients.
“Ultrasound enhancing agents have significantly advanced diagnostic quality in adult echocardiography over the years, and we are now seeing promising research supporting their safe and effective use in pediatric patients,” said Arash Sabati, MD, FACC, a pediatric cardiologist and non-invasive imaging specialist at Phoenix Children’s. “The availability of agents like Optison will further enhance diagnostic imaging for pediatric patients, helping to ensure the best possible care.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Recent Videos
Related Content
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025Article
The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025Article
For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
